145
Views
10
CrossRef citations to date
0
Altmetric
Original Research

Efficacy and Safety of Budesonide/Glycopyrrolate/Formoterol Fumarate Metered Dose Inhaler Formulated Using Co-Suspension Delivery Technology in Japanese Patients with COPD: A Subgroup Analysis of the KRONOS Study

, ORCID Icon, ORCID Icon, , , , ORCID Icon, ORCID Icon, , , , ORCID Icon, , ORCID Icon & ORCID Icon show all
Pages 2979-2991 | Published online: 23 Dec 2019

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (2)

Shu Hashimoto, Yuri Yoshida, Naoyuki Makita, Ryoko Sorimachi, Satoko Sugaya, Yoshifumi Arita, Nobuya Hayashi, Naoki Tashiro & Masakazu Ichinose. (2023) Real-World Evidence on the Diagnostic and Clinical Characteristics of Asthma in Japanese Patients with COPD: The ACO Japan Cohort Study. International Journal of Chronic Obstructive Pulmonary Disease 18, pages 37-46.
Read now
Masakazu Ichinose, Yasushi Fukushima, Yoshikazu Inoue, Osamu Hataji, Gary T Ferguson, Klaus F Rabe, Nobuya Hayashi, Hiroshi Okada, Mami Takikawa, Eric Bourne, Shaila Ballal, Kiernan DeAngelis, Magnus Aurivillius, Colin Reisner & Paul Dorinsky. (2019) Long-Term Safety and Efficacy of Budesonide/Glycopyrrolate/Formoterol Fumarate Metered Dose Inhaler Formulated Using Co-Suspension Delivery Technology in Japanese Patients with COPD. International Journal of Chronic Obstructive Pulmonary Disease 14, pages 2993-3002.
Read now

Articles from other publishers (8)

Shu Hashimoto, Ryoko Sorimachi, Naoyuki Makita, Naoki Tashiro, Satoko Sugaya, Yoshifumi Arita & Masakazu Ichinose. (2022) Real-World Status of Medical Care and Treatment of Chronic Obstructive Pulmonary Disease by Respiratory Specialists in Japan. Advances in Therapy 39:10, pages 4509-4521.
Crossref
Min Guo, Chuan Yu & Zenian Li. (2022) The Efficacy and Safety of Budesonide/Glycopyrronium/Formoterol in the Treatment of COPD in the Elderly. Contrast Media & Molecular Imaging 2022, pages 1-10.
Crossref
Stefanie C. Nigro & Diana M. Sobieraj. (2021) Budesonide/Glycopyrrolate/Formoterol Fumarate Co-suspension Metered Dose Inhaler: A Triple Therapy for the Treatment of Chronic Obstructive Pulmonary Disease. Annals of Pharmacotherapy 56:5, pages 582-591.
Crossref
Chih-Cheng Lai, Chao-Hsien Chen, Kuang-Hung Chen, Cheng-Yi Wang, Tsan-Ming Huang, Ya-Hui Wang & Hao-Chien Wang. (2022) The Impact of 52-Week Single Inhaler Device Triple Therapy versus Dual Therapy on the Mortality of COPD Patients: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Life 12:2, pages 173.
Crossref
Akira Koarai, Mitsuhiro Yamada, Tomohiro Ichikawa, Naoya Fujino, Tomotaka Kawayama & Hisatoshi Sugiura. (2022) Triple versus LAMA/LABA combination therapy for Japanese patients with COPD: A systematic review and meta-analysis. Respiratory Investigation 60:1, pages 90-98.
Crossref
Zhiguo Wang & Baofeng YangZhiguo Wang & Baofeng Yang. 2022. Polypharmacology. Polypharmacology 271 299 .
Young-A Heo. (2021) Budesonide/Glycopyrronium/Formoterol: A Review in COPD. Drugs 81:12, pages 1411-1422.
Crossref
Ying Huang, Pryseley Nkouibert Assam, Cong Feng, Rong Su, Paul Dorinsky & Michael Gillen. (2020) Ethnic pharmacokinetic comparison of budesonide/glycopyrrolate/formoterol fumarate metered dose inhaler (BGF MDI) between Asian and Western healthy subjects. Pulmonary Pharmacology & Therapeutics 64, pages 101976.
Crossref